PAX8 (+)/p63 (−) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC)
- 1 July 2010
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 34 (7) , 965-969
Abstract
Background Collecting duct carcinoma (CDC) is a relatively rare but aggressive type of renal malignancy with variable morphologic features. One of the World Health Organization diagnostic criteria for CDC is the exclusion of urothelial carcinoma of renal pelvis from the differential diagnosis. PAX8 is a novel lineage restricted transcription factor expressed in renal tubules. We investigated the expression pattern of PAX8 in CDC and its utility, in combination with p63, in resolving the differential diagnosis of CDC versus upper tract urothelial carcinoma (UUC). Design Archival tissues from 21 CDC and 34 UUC were retrieved from our institutional files. Immunohistochemistry for PAX8 and p63 were performed on routine and tissue microarray sections using standard immunohistochemistry protocol. Intensity of nuclear staining was evaluated for each marker and assigned an incremental 0, 1+, 2+, and 3+ score. Extent of staining was categorized as focal (75%). Results CDC: All 21 (100%) CDC were positive for PAX8. Intensity of expression was moderate to strong (2+/3+) in 19 cases (90%). Extent of staining was diffuse in 13 of 21 tumors. The p63 was positive in 3 of 21 (14%) CDC cases (PAX8+/p63+). UUC: The 34 UUC included 5 pT1, 4 pT2, and 25 pT3/pT4 tumors. Thirty-one of 34 (91.2%) UUC were negative for PAX8, whereas 33 of 34 (97%) were p63 positive. Staining intensity was moderate in 15 cases (44%), of which 12 were nonfocal or diffuse. The unique p63-negative UUC was a pT1 tumor that was also negative for PAX8 (PAX8−/p63−). Conclusions We propose the use of the combination of PAX8 and p63 in the diagnosis of poorly differentiated renal sinus epithelial neoplasms where the differential diagnosis includes CDC versus UUC. The immunoprofile of PAX8+/p63− supports the diagnosis of CDC with a sensitivity of 85.7% and a specificity of 100%. In contrast, a (PAX8−/p63+) profile supports the diagnosis of UUC with a sensitivity of 88.2% and a specificity of 100%. The inverse PAX8/p63 expression seen in CDC and UUC supports a renal tubular rather than an urothelial differentiation in CDC given the nephric lineage restriction of PAX8.Keywords
This publication has 15 references indexed in Scilit:
- GenitourinaryLaboratory Investigation, 2010
- Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical studyLaboratory Investigation, 2009
- Neoplasms of the Upper Urinary TractAdvances in Anatomic Pathology, 2008
- Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA MicroarrayAmerican Journal of Surgical Pathology, 2007
- Pax2 and Pax8 Regulate Branching Morphogenesis and Nephron Differentiation in the Developing KidneyJournal of the American Society of Nephrology, 2007
- PAX genes: Roles in development, pathophysiology, and cancerBiochemical Pharmacology, 2007
- 2004 WHO Classification of the Renal Tumors of the AdultsEuropean Urology, 2006
- Practical Methods for Tissue Microarray Construction2005
- Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinomaUrology, 2005
- Collecting duct carcinoma: an entity to be redefined?Virchows Archiv, 2004